New hope for leukemia patients stuck at a treatment Dead-End

NCT ID NCT06514534

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 34 times

Summary

This study tests a drug called asciminib in people with a specific type of chronic myeloid leukemia (CML) that has a genetic change called T315I. This change makes the leukemia harder to treat with standard drugs. The study includes about 20 adults whose cancer did not respond to or who could not take the drug ponatinib. The goal is to see if asciminib can control the cancer and improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Lille, 59037, France
Novartis Investigative Site
RECRUITING

Lyon, 69373, France
Novartis Investigative Site
RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Paris, 75475, France
Novartis Investigative Site
RECRUITING

Vandœuvre-lès-Nancy, 54511, France

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOID LEUKEMIA (CML)